Royalty Pharma plc (NASDAQ:RPRX) has been given an average recommendation of "Hold" by the ten brokerages that are covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $51.88.
Several analysts recently commented on RPRX shares. UBS Group upgraded shares of Royalty Pharma from a "neutral" rating to a "buy" rating and reduced their price target for the company from $52.00 to $51.00 in a research report on Monday, November 9th. Zacks Investment Research downgraded shares of Royalty Pharma from a "buy" rating to a "hold" rating in a research report on Friday, February 5th.
RPRX stock opened at $48.02 on Tuesday. The company has a fifty day moving average price of $49.12 and a 200 day moving average price of $44.05. Royalty Pharma has a 12 month low of $34.80 and a 12 month high of $56.50. The company has a current ratio of 10.31, a quick ratio of 10.31 and a debt-to-equity ratio of 0.59.
Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Wednesday, February 17th. The biopharmaceutical company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.70 by ($0.42). Analysts forecast that Royalty Pharma will post 2.44 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 15th. Shareholders of record on Friday, February 19th will be paid a $0.17 dividend. This is a boost from Royalty Pharma's previous quarterly dividend of $0.15. This represents a $0.68 annualized dividend and a yield of 1.42%. The ex-dividend date of this dividend is Thursday, February 18th.
In other news, major shareholder Adage Capital Partners Gp, L.L sold 7,301,050 shares of the company's stock in a transaction on Friday, December 18th. The shares were sold at an average price of $43.92, for a total transaction of $320,662,116.00. Corporate insiders own 2.50% of the company's stock.
Several large investors have recently bought and sold shares of the company. American International Group Inc. grew its stake in shares of Royalty Pharma by 24.4% during the 4th quarter. American International Group Inc. now owns 1,975 shares of the biopharmaceutical company's stock worth $99,000 after purchasing an additional 388 shares during the period. IFP Advisors Inc grew its stake in shares of Royalty Pharma by 112.5% during the 3rd quarter. IFP Advisors Inc now owns 850 shares of the biopharmaceutical company's stock worth $36,000 after purchasing an additional 450 shares during the period. Profund Advisors LLC grew its stake in shares of Royalty Pharma by 7.6% during the 4th quarter. Profund Advisors LLC now owns 7,069 shares of the biopharmaceutical company's stock worth $354,000 after purchasing an additional 500 shares during the period. Neo Ivy Capital Management grew its stake in Royalty Pharma by 65.5% in the 3rd quarter. Neo Ivy Capital Management now owns 1,824 shares of the biopharmaceutical company's stock valued at $76,000 after acquiring an additional 722 shares during the last quarter. Finally, Oxler Private Wealth LLC acquired a new stake in Royalty Pharma in the 4th quarter valued at about $62,000. 40.85% of the stock is currently owned by institutional investors and hedge funds.
Royalty Pharma Company Profile
Royalty Pharma plc operates in the biopharmaceutical industry. The company operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. It is involved in the identification, evaluation, and acquisition of royalties and royalty-related assets on various biopharmaceutical therapies.
See Also: Technical Analysis of Stocks and What It Means
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Analysts Hate These 12 Stocks
When a single Wall Street analyst downgrades one of your stocks, you might think they are just having a bad day or have an incorrect investment thesis. One downgrade typically won't have a significant impact on the price of one of your stocks, but what if analysts repeatedly downgraded a company over the last 30, 60, or 90 days? You would know something is seriously wrong.
Today, we invite you to take a free exclusive look at our up-to-the-minute list of 12 "Most Downgraded" stocks. These are true strong sell stocks. Analysts are abandoning them in droves and issuing rare downgrades and sell ratings. If any of these stocks are lurking around in your portfolio, seriously consider whether or not they still belong in your portfolio.
View the "Analysts Hate These 12 Stocks".